Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05291689 · ClinicalTrials.gov registry record · Phase 2
A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC
A Phase 2 study, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- Completed
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT05291689 is a Phase 2 study that has completed, run by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company). The registered enrollment target is 39 participants.
The verdict
NCT05291689, a Phase 2 study, has completed, sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)
Interventions
- DRUG MORF-057
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-04-13 |
| Est. Completion | 2025-02-19 |
| Phase | Phase 2 |
Sponsor
Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company)4 total trials
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05291689
The ClinicalTrials.gov registry entry for NCT05291689 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MORF-057 is the first listed.
NCT05291689 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05291689 about?
NCT05291689 is a clinical study titled "A Phase 2a Open-Label Study to Evaluate the Efficacy and Safety of MORF-057 in Adults With UC". This is an open-label, single arm, multicenter, Phase 2a study evaluating the efficacy, safety, and tolerability of MORF-057 in adult patients with Moderately to Severely Active Ulcerative Colitis (UC)
What is the current status of trial NCT05291689?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2022-04-13. Estimated completion is 2025-02-19.
What interventions are being tested in trial NCT05291689?
The interventions under investigation include: MORF-057 (DRUG).
Who is sponsoring clinical trial NCT05291689?
This trial is sponsored by Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company), which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.